{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:16:59Z","timestamp":1790806619662,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jns.2026.125806","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:53:48Z","timestamp":1770684828000},"page":"125806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["\u03b1-synuclein monoclonal antibodies in Parkinson's disease: A failed promise or unmet potential?"],"prefix":"10.1016","volume":"482","author":[{"given":"Mark","family":"Messak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Abdelmageed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef A.","family":"Khattab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gergis","family":"Altalab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Mandour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Shaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2026.125806_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2024.1498756","article-title":"Global, regional, national epidemiology and trends of Parkinson\u2019s disease from 1990 to 2021: findings from the global burden of disease study 2021","volume":"16","author":"Luo","year":"2025","journal-title":"Front. Aging Neurosci."},{"issue":"Suppl. 1","key":"10.1016\/j.jns.2026.125806_bb0010","article-title":"Neuropathology of Parkinson disease","volume":"46","author":"Dickson","year":"2018","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jns.2026.125806_bb0015","doi-asserted-by":"crossref","DOI":"10.1592\/phco.27.12part2.155S","article-title":"Overview of Parkinson\u2019s disease","volume":"27","author":"Lew","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jns.2026.125806_bb0020","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"\u03b1-Synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.jns.2026.125806_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2022.02.006","article-title":"\u0391-Synuclein in Parkinson\u2019s disease and advances in detection","volume":"529","author":"Chen","year":"2022","journal-title":"Clin. Chim. Acta Int. J. Clin. Chem."},{"key":"10.1016\/j.jns.2026.125806_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2018.00080","article-title":"Mechanisms of \u03b1-Synuclein induced Synaptopathy in Parkinson\u2019s disease","volume":"12","author":"Bridi","year":"2018","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.jns.2026.125806_bb0035","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jchemneu.2016.06.001","article-title":"Alpha-synuclein modulates dopamine neurotransmission","volume":"83\u201384","author":"Butler","year":"2017","journal-title":"J. Chem. Neuroanat."},{"key":"10.1016\/j.jns.2026.125806_bb0040","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1523\/JNEUROSCI.22-08-03090.2002","article-title":"A role for \u03b1-Synuclein in the regulation of dopamine biosynthesis","volume":"22","author":"Perez","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jns.2026.125806_bb0045","doi-asserted-by":"crossref","DOI":"10.1002\/mds.27414","article-title":"Targeted therapies for Parkinson\u2019s disease: from genetics to the clinic","volume":"33","author":"Sardi","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2026.125806_bb0050","doi-asserted-by":"crossref","first-page":"29","DOI":"10.5607\/en21039","article-title":"Conformation-specific antibodies targeting aggregated forms of \u03b1-synuclein block the propagation of Synucleinopathy","volume":"31","author":"Choi","year":"2022","journal-title":"Experiment. Neurobiol."},{"key":"10.1016\/j.jns.2026.125806_bb0055","doi-asserted-by":"crossref","DOI":"10.1523\/JNEUROSCI.1292-12.2012","article-title":"Antibody-aided clearance of extracellular \u03b1-synuclein prevents cell-to-cell aggregate transmission","volume":"32","author":"Bae","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jns.2026.125806_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2014.05.009","article-title":"Immunotherapy targeting \u03b1-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] \u03b1-synuclein mice","volume":"69","author":"Lindstr\u00f6m","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jns.2026.125806_bb0065","doi-asserted-by":"crossref","DOI":"10.1002\/mds.29784","article-title":"Randomized phase I trial of the \u03b1-Synuclein antibody Lu AF82422","volume":"39","author":"Buur","year":"2024","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2026.125806_bb0070","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2203395","article-title":"Trial of Cinpanemab in early Parkinson\u2019s disease","volume":"387","author":"Lang","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2026.125806_bb0075","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/mds.27738","article-title":"Randomized phase I clinical trial of anti\u2013\u03b1-synuclein antibody BIIB054","volume":"34","author":"Brys","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2026.125806_bb0080","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaneurol.2018.1487","article-title":"Safety and tolerability of multiple ascending doses of PRX002\/RG7935, an anti\u2013\u03b1-Synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial","volume":"75","author":"Jankovic","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jns.2026.125806_bb0085","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa2202867","article-title":"Trial of Prasinezumab in early-stage Parkinson\u2019s disease","volume":"387","author":"Pagano","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2026.125806_bb0090","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3389\/fnmol.2019.00299","article-title":"Targeting alpha-Synuclein as a therapy for Parkinson\u2019s disease","volume":"12","author":"Fields","year":"2019","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.jns.2026.125806_bb0095","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/mds.29318","article-title":"Who ever said it would be easy? Reflecting on two clinical trials targeting \u03b1-Synuclein","volume":"38","author":"Jensen","year":"2023","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2026.125806_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbapap.2023.140943","article-title":"Antibodies and \u03b1-synuclein: what to target against Parkinson\u2019s disease?","volume":"1872","author":"Otzen","year":"2024","journal-title":"Biochim. Biophys. Acta, Proteins Proteomics"},{"key":"10.1016\/j.jns.2026.125806_bb0105","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S1474-4422(11)70213-7","article-title":"Pathological roles of \u03b1-synuclein in neurological disorders","volume":"10","author":"Vekrellis","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2026.125806_bb0110","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.expneurol.2008.06.004","article-title":"Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration","volume":"213","author":"Mollenhauer","year":"2008","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.jns.2026.125806_bb0115","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-41382-0","article-title":"Analysis of clinical failure of anti-tau and anti-synuclein antibodies in neurodegeneration using a quantitative systems pharmacology model","volume":"13","author":"Geerts","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jns.2026.125806_bb0120","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ab.2016.06.025","article-title":"Determination of half-maximal inhibitory concentration using biosensor-based protein interaction analysis","volume":"508","author":"Aykul","year":"2016","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.jns.2026.125806_bb0125","article-title":"A brain-penetrant bispecific antibody lowers oligomeric alpha-synuclein and activates microglia in a mouse model of alpha-synuclein pathology","volume":"22","author":"Sehlin","year":"2024","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jns.2026.125806_bb0130","article-title":"Brain-targeted liposomes loaded with monoclonal antibodies reduce alpha-synuclein aggregation and improve behavioral symptoms in Parkinson\u2019s disease","volume":"35","author":"Sela","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jns.2026.125806_bb0135","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/mdc3.13710","article-title":"\u0391-Synuclein seed amplification assays in the diagnosis of Synucleinopathies using cerebrospinal fluid\u2014a systematic review and Meta-analysis","volume":"10","author":"Grossauer","year":"2023","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.jns.2026.125806_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2023.120730","article-title":"Alpha-synuclein in skin as a high-quality biomarker for Parkinson\u2019s disease","volume":"451","author":"Peng","year":"2023","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2026.125806_bb0145","article-title":"RT-QuIC: a highly promising diagnostic method for neurodegenerative diseases\u2014advantages and limitations","volume":"16","author":"Kon\u00ed\u010dkov\u00e1","year":"2025","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jns.2026.125806_bb0150","doi-asserted-by":"crossref","first-page":"8728","DOI":"10.1007\/s12035-018-1007-y","article-title":"Detecting alpha Synuclein seeding activity in formaldehyde-fixed MSA patient tissue by PMCA","volume":"55","author":"Becker","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.jns.2026.125806_bb0155","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/brain\/awab431","article-title":"Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies","volume":"145","author":"Poggiolini","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.jns.2026.125806_bb0160","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/mds.27646","article-title":"Comparative study of cerebrospinal fluid \u03b1-synuclein seeding aggregation assays for diagnosis of Parkinson\u2019s disease","volume":"34","author":"Kang","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2026.125806_bb0165","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1001\/jama.2024.0792","article-title":"Skin biopsy detection of phosphorylated \u03b1-Synuclein in patients with Synucleinopathies","volume":"331","author":"Gibbons","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jns.2026.125806_bb0170","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1212\/WNL.0000000000002919","article-title":"The diagnostic discrimination of cutaneous \u03b1-synuclein deposition in Parkinson disease","volume":"87","author":"Gibbons","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2026.125806_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaneurol.2020.3311","article-title":"Skin \u03b1-Synuclein aggregation seeding activity as a novel biomarker for Parkinson disease","volume":"78","author":"Wang","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jns.2026.125806_bb0180","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.nbd.2017.07.018","article-title":"Distinct \u03b1-Synuclein strains and implications for heterogeneity among \u03b1-Synucleinopathies","volume":"109","author":"Peng","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jns.2026.125806_bb0185","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1001\/archneur.58.2.186","article-title":"Synucleinopathies: clinical and pathological implications","volume":"58","author":"Galvin","year":"2001","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2026.125806_bb0190","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241713199","article-title":"Beyond strains: molecular diversity in alpha-Synuclein at the Center of Disease Heterogeneity","volume":"24","author":"Wojewska","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jns.2026.125806_bb0195","article-title":"\u0391-Synuclein strain dynamics correlate with cognitive shifts in Parkinson\u2019s disease","author":"Gadhave","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.jns.2026.125806_bb0200","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1186\/s40001-023-01512-w","article-title":"The FDA-approved anti-amyloid-\u03b2 monoclonal antibodies for the treatment of Alzheimer\u2019s disease: a systematic review and meta-analysis of randomized controlled trials","volume":"28","author":"Wu","year":"2023","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.jns.2026.125806_bb0205","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2026.125806_bb0210","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"10.1016\/j.jns.2026.125806_bb0215","article-title":"Lecanemab in patients with early Alzheimer\u2019s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"McDade","year":"2022","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"10.1016\/j.jns.2026.125806_bb0220","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of Aducanumab in early Alzheimer\u2019s disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J. Prev Alzheim. Dis."},{"key":"10.1016\/j.jns.2026.125806_bb0225","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.trci.2016.06.002","article-title":"First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer\u2019s disease","volume":"2","author":"Ferrero","year":"2016","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.jns.2026.125806_bb0230","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004568","article-title":"Efficacy and safety of passive immunotherapies targeting amyloid beta in Alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"22","author":"Tonegawa-Kuji","year":"2025","journal-title":"PLoS Med."},{"key":"10.1016\/j.jns.2026.125806_bb0235","doi-asserted-by":"crossref","first-page":"8097","DOI":"10.1002\/alz.14317","article-title":"Amyloid PET detects the deposition of brain A\u03b2 earlier than CSF fluid biomarkers","volume":"20","author":"Lowe","year":"2024","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jns.2026.125806_bb0240","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1136\/practneurol-2019-002468","article-title":"Amyloid PET imaging in clinical practice","volume":"20","author":"Kolanko","year":"2020","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.jns.2026.125806_bb0245","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00415-019-09348-3","article-title":"Does the MDS-UPDRS provide the precision to assess progression in early Parkinson\u2019s disease? Learnings from the Parkinson\u2019s progression marker initiative cohort","volume":"266","author":"Regnault","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2026.125806_bb0250","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3906\/sag-2008-253","article-title":"Dopamine transporter SPECT imaging in Parkinson\u2019s disease and parkinsonian disorders","volume":"51","author":"Akdemir","year":"2021","journal-title":"Turk. J. Med. Sci."},{"key":"10.1016\/j.jns.2026.125806_bb0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-024-00787-9","article-title":"Positron emission tomography tracers for synucleinopathies","volume":"20","author":"Xiang","year":"2025","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.jns.2026.125806_bb0260","doi-asserted-by":"crossref","DOI":"10.3390\/ph14090847","article-title":"Alpha-synuclein PET tracer development\u2014an overview about current efforts","volume":"14","author":"Korat","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jns.2026.125806_bb0265","doi-asserted-by":"crossref","first-page":"7124","DOI":"10.3390\/ijms25137124","article-title":"Binding affinity determination in drug design: insights from lock and key, induced fit, conformational selection, and inhibitor trapping models","volume":"25","author":"Spassov","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jns.2026.125806_bb0270","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1039\/D5MD00057B","article-title":"The development of a PET radiotracer for imaging alpha synuclein aggregates in Parkinson\u2019s disease","volume":"16","author":"Tian","year":"2025","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.jns.2026.125806_bb0275","article-title":"Delivery of monoclonal antibodies to the brain: the impact of nanocarrier structure","author":"Pineiro-Alonso","year":"2025","journal-title":"Drug Deliv. Transl. Res."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26000882?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X26000882?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T13:32:02Z","timestamp":1771680722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X26000882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":55,"alternative-id":["S0022510X26000882"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2026.125806","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u03b1-synuclein monoclonal antibodies in Parkinson's disease: A failed promise or unmet potential?","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2026.125806","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"125806"}}